FDA expands probe into AstraZeneca Covid-19 vaccine candidate

1st Oct 2020 07:30

(Sharecast News) - America's main health regulator, the Food and Drug Administration, has widened its investigation into the adverse event related to one patient in AstraZeneca's ongoing phase three clinical trial of its Covid-19 vaccine candidate, Reuters reported, which remains on hold in the States.

While the expanded probe increases the chances of longer delays before a potential restart of the trial in that country, it does mean that the FDA thinks there were safety issues linked to the vaccine, rather that it intends to be through.

-- More to follow --